Home › Burkitt Lymphoma › California
Burkitt Lymphoma clinical trials in California
20 studies for Burkitt Lymphoma are looking for participants at sites in California.
Cities in California
- Los Angeles10 studies
- Baldwin Park9 studies
- Orange9 studies
- San Francisco8 studies
- Mountain View6 studies
- Oakland6 studies
- San Diego5 studies
- Sacramento5 studies
- Irvine4 studies
- San Bernardino4 studies
- Fresno4 studies
- Long Beach4 studies
- Downey3 studies
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03739814A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Miller Children's and Women's Hospital Long Beach, Long Beach
- and 9 more
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Sep 28, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Loma Linda University Medical Center, Loma Linda
- Miller Children's and Women's Hospital Long Beach, Long Beach
- UCSF Benioff Children's Hospital Oakland, Oakland
- and 4 more
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- UC Irvine, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- Community Cancer Institute, Clovis
- UC Irvine Health Cancer Center-Newport, Costa Mesa
- and 26 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Sep 2, 2026 · NCT03150693A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente Downey Medical Center, Downey
- Kaiser Permanente-Fontana, Fontana
- and 14 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- and 14 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Palo Alto
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07069699Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 12 to 55 · All sexes · Updated Jul 14, 2026 · NCT07133997Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Duarte
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Jul 13, 2026 · NCT07109219Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT04545762Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- and 1 more
RecruitingPhase 2
Ages 18 to 54 · All sexes · Updated Mar 17, 2026 · NCT06918431Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2025 · NCT04260022Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
RecruitingPhase 1/2
Ages 15 to 50 · All sexes · Updated Sep 9, 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- City of Hope, Duarte
- Children's Hospital Los Angeles, Los Angeles
- UCLA Mattel Children's Hospital, Los Angeles
- and 2 more
RecruitingPhase 2
Ages 1 to 25 · All sexes · Updated May 4, 2025 · NCT03509961From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.